DeCure's autonomous Metabolic AI scientist is researching a drug-repurposing hypothesis for iron metabolism disease — screening already-approved drugs against its 34-gene Open Targets disease module to publish open-access research. Research is fast; the path to publication is funded in milestone stages.
Disease moduleIron metabolism disease maps to a 34-gene Open Targets module — the target space DeCure's AI scientist screens approved drugs against.
DeCure.ai methodSignature reversal (LINCS) plus network proximity (STRING) rank already-approved drugs likely to perturb this module — the same engine that produces DeCure.ai's repurposing hypotheses.
Repurposing thesisScreening approved medicines against this disease module, then publishing the evidence for the strongest candidate. Known pharmacology and human exposure data make the first question sharper — they do not establish safety or efficacy in a new indication.
Research record
01
ResearchComing soon
Candidate research + dossier — target rationale, drug-repurposing thesis and evidence pack.proof: Published dossier + on-chain hash
02
ValidationComing soon
In-vitro biological validation at a contract research org (CRO).proof: CRO contract + in-vitro report
03
Peer review & paperComing soon
Peer-reviewed paper published open-access (preprint + journal).proof: DOI + open-access link + on-chain hash
Current lead
No approved-drug candidate for iron metabolism disease is corroborated in the literature DeepSearch retrieved. Some conditions are managed with non-pharmacological care — a device, surgery or physical therapy — rather than a medicine; that may be the case here, or the literature we found may simply be too sparse yet to support a drug-repurposing angle.
Molecular view
ARF like GTPase 8B (ARL8B) — ARL8B is one of the genes genetically linked to this disease in Open Targets — shown as context, not as a drug target we're pursuing: no approved-drug candidate for this disease is yet corroborated in the literature we found.
Loading structure…
helix sheet gtpdrag to rotate · scroll to zoom
RCSB Protein Data Bank · entry 8JCA · 1.65 Å · ligand GUANOSINE-5'-TRIPHOSPHATE (GTP). Experimental structure, not a prediction.
What the evidence adds up to
A 2008 review notes that iron deficiency affects over 2 billion people worldwide, while in the United States 9 million are iron deficient and 1 million are at genetic risk of iron overload. A 2017 review describes inherited disorders of iron metabolism, covering normal iron metabolism, the mechanisms of disruption for each pathology, clinical manifestations, laboratory changes, and therapy principles. A 2015 review states that chronic iron overload, whether genetic or acquired, causes multi-organ damage in adults and children, affecting quality of life and life expectancy; diagnosis increasingly relies on non-invasive clinical, biological and imaging data, and treatment is either venesection or chelation depending on the cause.
A 2014 review reports that two oral agents, deferasirox and deferiprone, have become available in the preceding eight years, used at higher doses and in combination with the older agent desferrioxamine. Trial data showed efficacy in preventing or treating toxicity from iron overload. The primary use of chelation has been transfusional iron overload, with increasing evidence for benefit in myelodysplasia, pre-stem cell transplantation, and potentially in malignancies. Two new chelators were in development, one in phase 3 trials and one in preliminary animal studies. A 2024 expert opinion states that dysregulation of the hepcidin-ferroportin axis is a hallmark of iron overload pathogenesis; hereditary hemochromatosis and iron-loading anemias are characterised by hepcidin deficiency, making hepcidin a novel therapeutic target. Modulators of hepcidin expression and hepcidin-mimicking molecules are emerging strategies, but challenges remain in optimising dosing for a narrow treatment window and improving specificity to iron metabolism pathways. Long-term studies are needed to assess benefits and risks, and potential utility in combination with existing guidelines.
A 2024 study in a mouse model of intervertebral disc degeneration (IDD) found that the pathological environment, with oxidative stress and pro-inflammatory cytokines, enhanced iron influx by upregulating transferrin receptor-1 (TFR1) in a HIF-2α dependent manner. Excessive iron accumulation induced chondrocyte ferroptosis, exacerbated oxidative stress, and triggered innate immune responses via c-GAS/STING by promoting mitochondrial damage and mtDNA release. Inhibiting STING with siRNA or reducing mtDNA replication with ethidium bromide alleviated iron-overload-induced degeneration of cartilage endplate chondrocytes. The authors suggest targeting TFR1 to maintain iron homeostasis as a potential therapeutic approach for IDD, but this remains at the preclinical stage.
What is still missing are long-term safety and efficacy data for hepcidin-targeting therapies in humans, optimal dosing regimens that avoid toxicity, and specificity for iron metabolism pathways without off-target effects. For the TFR1/HIF-2α mechanism in disc degeneration, no human trials exist, and the clinical relevance of this pathway in patients with iron overload or degenerative disease is unproven. Funding for phase 3 trials of new chelators and for translational studies of hepcidin modulators is needed, as is patient stratification by genetic and acquired iron-loading aetiologies.
Evidence
Retrieved by DeepSearch across 234,678,978 indexed works and resolved on OpenAlex — ranked by citations, including the results that did not work.
Current Opinion in Hematology · 2014 · 58 citations
Iron chelation
AbstractPURPOSE OF REVIEW: This review provides an update on advances in the area of iron chelation therapy, including new indications and uses of currently available agents, and preliminary data on potential new agents in development. RECENT FINDINGS: Two new oral agents, deferasirox and deferiprone, have become available in the last 8 years. These have been used at higher doses, in combination with the older agent desferrioxamine, and recent trials' data have shown efficacy in preventing or treating the toxicity associated with iron overload. Advances in measuring tissue iron noninvasively by magnetic resonance techniques have enhanced diagnostic capabilities and allowed for more precise measurement and monitoring of iron burden. The primary use of chelation has been transfusional iron overload. There is now an increasing body of evidence for the benefits of iron chelation in myelodysplasia, pre-stem cell transplantation, and potentially in the treatment of malignancies. Two new iron chelators are in development, one in phase 3 clinical trials and the other in preliminary animal studies. SUMMARY: The last decade has ushered in a new era in iron chelation therapy. Coupled with advances in tissue iron quantitation, there is tremendous promise of an individually tailored approach to chelation, and subsequent reduction in morbidity and mortality.
Expert Review of Gastroenterology & Hepatology · 2015 · 55 citations · open access
Optimizing the diagnosis and the treatment of iron overload diseases
AbstractA number of human disorders are related to chronic iron overload, either of genetic or acquired origin. The multi-organ damage produced by iron excess leads, in adults and in children, to severe clinical consequences, affecting both quality of life and life expectancy. The diagnosis is increasingly based on a non-invasive strategy, resorting to clinical, biological and imaging data. The treatment rests on either venesection or chelation therapy, depending on the etiology. Major advances in the fields of molecular biology, pharmacology, and biotechnology pave the road for key improvements in the diagnostic and therapeutic management of the patients.
Journal of Orthopaedic Translation · 2024 · 37 citations · open access
HIF-2α/TFR1 mediated iron homeostasis disruption aggravates cartilage endplate degeneration through ferroptotic damage and mtDNA release: A new mechanism of intervertebral disc degeneration
AbstractBackgroud: Iron overload is a prevalent condition in the elderly, often associated with various degenerative diseases, including intervertebral disc degeneration (IDD). Nevertheless, the mechanisms responsible for iron ion accumulation in tissues and the mechanism that regulate iron homeostasis remain unclear. Transferrin receptor-1 (TFR1) serves as the primary cellular iron gate, playing a pivotal role in controlling intracellular iron levels, however its involvement in IDD pathogenesis and the underlying mechanism remains obscure. Methods: Firstly, IDD mice model was established to determine the iron metabolism associated proteins changes during IDD progression. Then CEP chondrocytes were isolated and treated with TBHP or pro-inflammatory cytokines to mimic pathological environment, western blotting, immunofluorescence assay and tissue staining were employed to explore the underlying mechanisms. Lastly, TfR1 siRNA and Feristatin II were employed and the degeneration of IDD was examined using micro-CT and immunohistochemical analysis. Results: We found that the IDD pathological environment, characterized by oxidative stress and pro-inflammatory cytokines, could enhance iron influx by upregulating TFR1 expression in a HIF-2α dependent manner. Excessive iron accumulation not only induces chondrocytes ferroptosis and exacerbates oxidative stress, but also triggers the innate immune response mediated by c-GAS/STING, by promoting mitochondrial damage and the release of mtDNA. The inhibition of STING through siRNA or the reduction of mtDNA replication using ethidium bromide alleviated the degeneration of CEP chondrocytes induced by iron overload. Conclusion: Our study systemically explored the role of TFR1 mediated iron homeostasis in IDD and its underlying mechanisms, implying that targeting TFR1 to maintain balanced iron homeostasis could offer a promising therapeutic approach for IDD management. The translational potential of this article: Our study demonstrated the close link between iron metabolism dysfunction and IDD, indicated that targeting TfR1 may be a novel therapeutic strategy for IDD.
Expert Opinion on Therapeutic Targets · 2024 · 17 citations
Hepcidin as a therapeutic target in iron overload
AbstractINTRODUCTION: Dysregulation of the hepcidin-ferroportin axis is a hallmark in the pathogenesis of iron overload, ultimately leading to end-organ injury. Hereditary hemochromatosis and iron-loading anemias are characterized by a hepcidin deficiency, making hepcidin a novel therapeutic target for preventing and managing iron overload. AREAS COVERED: Modulators of hepcidin expression and molecules mimicking hepcidin are emerging as highly promising therapeutic strategies. We present a summary of results from preclinical and clinical trials of such therapies in models of iron overload. EXPERT OPINION: Current treatment alternatives in iron overload fail to address the underlying hepcidin deficiency - and may even exacerbate it. Until hepcidin-targeting therapies become available, several challenges remain, including the need to optimize dosing in order to manage the narrow treatment window and improving specificity in targeting iron metabolism pathways exclusively. Long-term studies are crucial to fully assess both the benefits and risks of these therapies and to explore their potential utility in combination with existing treatment guidelines. Furthermore, these therapies are expected to have applications, particularly in addressing other iron-maldistributed disorders, as seen in anemia of chronic disease and inflammation.
Pediatric Hematology/Oncology and Immunopathology · 2017 · 0 citations · open access
Inherited disorders of iron metabolism
AbstractThe presented review provides information about genetic diseases associated with impaired iron metabolism, includes the main aspects of normal iron metabolism, the mechanisms of its disruption for each described pathology. The review also presents information about major clinical manifestation, changes in laboratory parameters and the principles of therapy.
North American Journal of Medicine and Science · 2008 · 0 citations
Research Update on Iron Metabolism and Its Regulation Mechanisms
AbstractIron metabolism disorder is an important public health problem both in the United States and developing world. Iron deficiency cases are over 2 billion worldwide. In theU.S., 9 million people are iron deficient and 1 million are at genetic risk of iron overload. Recent advances in research on iron-related diseases, coupled with new insights into the molecular mechanisms for iron metabolism, have strengthened our understanding of iron metabolism and iron disorder and have the potential to improve clinical and laboratory assessments of patients. In this article, I aim to provide a brief summary of recent developments in the molecular mechanisms underlying iron metabolism.
Disease module: DeepOracle (Open Targets). Structures: RDKit from PubChem SMILES. Literature: retrieved by DeepSearch across 234,678,978 indexed works (targeted per-candidate search), resolved on OpenAlex.
DeCure is a research and publication project, not medical advice and not a treatment. "DeCure for X" describes a research goal, not a claim that a cure exists. Backing a cure is a contribution to fund the research — it is not an investment, and confers no yield, royalty, equity or IP ownership. Papers are published open-access by the DeCure.ai DAO.
